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Metastasis, the invasion of distant tissues, is a poor prognostic sign in
cancer. Cell motility is involved in mediating metastasis.
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Overexpression of thymosin (315 has been shown to cause increased motility.
P120cas is part of a complex of proteins that is critical for cell-cell adhesion,
though the precise function of pl20cas is not known. The complex is also involved
in motility, differentiation, and signal transduction.

Given the functions of these

two proteins, it is hypothesized that thymosin (315 expression should be increased
and pl20cas expression should be decreased in the metastatic phenotype.

Human

cancers were assessed for alterations in these potential prognostic markers.

The

expression of thymosin (315 was examined in human breast cancer, and pl20cas
was examined in human colorectal cancer.
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using
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Surgical pathology slides were
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methods.

Thymosin

(315

expression was found to be increased in malignant breast tissue compared with
benign breast epithelium (p = 0.0002) .
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Expression of the adhesion-related protein pl20cas is decreased in colorectal
cancer compared to benign epithelium.

Decreased pl20cas expression correlates

with

nodal

advanced

stage

(p

=

0.0470),

lymphovascular invasion (p = 0.0156).

metastasis

(p

=

0.0426),

and

Decreased pl20cas expression is also

associated with larger tumors (p = 0.0120).

Loss of pl20cas furthermore

corresponds with decreased survival (p = 0.0126) and decreased disease-free
survival (p = 0.0313).
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General Introduction

Cancer is not one disease but a spectrum of related diseases often
with very different behaviors and implications. Nevertheless, cancer has
historically been grouped together as one entity, and in fact, these diseases
share some fundamental similarities in their pathology.

When considered

as a whole, cancer undeniably has an enormous impact on humankind.
In this country, well over one million people will be diagnosed with
cancer this year. Over half a million will die cancer-related deaths this
year, making this the second leading cause of death next to heart disease.
About one half of all Americans will develop a cancer in their lifetime. [1]
An aging population and our ever increasing ability to detect new cases
promises to increase the incidence of cancer even further. While it may be
easy to quantitate the number of individuals affected or killed, the cost to
society both financially and emotionally is harder to assess. Hopefully,
medicine in the next century will be able to face this challenge with
improved therapy.
All cancers have at their heart the same underlying pathology. Cells
derived from within the victim’s body grow uninhibited and can invade into
surrounding tissues or implant at distant sites. The differentiation of the
cancer defines the disease and separates it from other cancers. Thus a
cancer that arises in and architecturally resembles the ducts in the
pancreas cannot be considered synonymous with a cancer arising in and
resembling the glands of the prostate. While the end results may be
dramatically different, there are many similarities in the path that a cell
must travel to give rise to any cancer.
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Contemporary theory holds that every cancer derives from a single
cell. This is called the clonal hypothesis. That cell must undergo a series
of nonlethal genetic changes to become a full-blown carcinoma.

In other

words, a normal cell will suffer one insult and give rise to a slightly more
nefarious clone of cells. One cell within this clone will theoretically suffer
yet another change that will allow its progeny to become the dominant cells
within the new growth until one of these cells is mutated into yet a more
lethal clone. This is called clonal expansion. [2, 3]
Much of this theory is old. Almost as long as pathologists have
looked at cancer under the microscope, they have recognized that though
cancers often resemble their tissue of origin, it is the cancers that grow in a
seemingly unregulated pattern, very much unlike their native tissue, that
behave badly.

In addition, carcinomas in their earliest form — small,

contained within the epithelial cell layer, or arising in an otherwise benign
growth — are often relatively normal appearing indicating that the further
advanced lesions have suffered more changes separating them from their
host. [4]
The idea that genetic changes are at the heart of the development of
cancer from normal tissue is somewhat newer[5]. And only recently have
the specific genetic events responsible for this metamorphosis begun to be
appreciated.

Much of this knowledge comes from colorectal cancer, which

serves as the best model to study this process. As previously hypothesized
in the multi-step theory, cells suffer a series of genetic changes that propel
them through the development from a benign growth to a carcinoma.
Even the earliest growth, which in the colorectal model is a small
adenomatous polyp, is monoclonal in origin whereas the surrounding
tissue is polyclonal [61. Polyps seem to preferentially arise from areas of
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epithelial hyperproliferation indicating that the normal tissue is altered
even before a polyp forms[7, 8]. Genetic changes seem to occur in two basic
ways — genes that normally suppress tumor growth, tumor suppressor
genes, are lost or altered such that they cannot function in that manner,
while simultaneously genes that normally promote growth in a regulated
fashion, proto-oncogenes, are altered such that they lose their regulation
and promote uncontrolled growth. The mechanisms by which these
changes can occur are multi-fold and include loss of chromosomes or
pieces of chromosomes, chromosomal rearrangements, spontaneous
mutations, and viral-mediated changes.

Furthermore, these insults can be

caused by various environmental factors or they can be inherited. [4]
As a tumor progresses from a benign growth and becomes
increasingly more uninhibited and develops histopathological features
more suggestive of carcinoma, the number of genetic changes detected
increases. While it appears that these changes may often occur in a
preferred sequence, it is the accumulation of these changes and not the
order in which they arise that determines the tumor’s biology. [3]
If genetic changes are the basis for the development of a cancer from
a normal cell, these alterations must mediate a number of functions found
in the cancer but not in the normal tissue. For instance these changes
must be able to promote the unregulated growth not only of the clonal
portions of the tumor but also of the connective tissue elements as well —
this often requires the proliferation of nonclonal cellular elements. Thus
the ability of a tumor to recruit the formation of new vessels, angiogenesis,
must be mediated by genetic changes. Genetic changes must also be
responsible for the ability of a tumor to invade and travel through tissues, to
gain access to the blood stream or lymphatics, as well as to attach to a new
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site and thrive there. The ability of tumors to evade the body’s mechanisms
of destroying cells with foreign elements must derive from genetic changes.
The functions listed above are all complex and each involves multiple
components.
Thus while it is obvious now that in cancer there are genes altered
and hence proteins directly changed in nature or expression, there must
also be a whole host of changes in cellular organization and protein
composition that are indirectly caused by insults the cell has suffered in its
DNA. In other words the proteins altered at the DNA level must be involved
in complex pathways that cause alterations in expression, localization,
splicing and destruction of mRNA and proteins where the code is not
directly affected at the DNA level.
The examination of the totality of changes in human cancers can
serve many functions. At the most fundamental level, associating the
changes in cell structure with the related changes in function will allow
science to gain a better understanding of the various molecular components
of the cell and their functions in the normal state as well as in disease. The
understanding of how cancer cells differ from normal cells could also
conceivably provide targets for more rational cancer therapy.
Careful documentation of the changes in neoplastic cells may allow
for better diagnosis of cancer when pieces of tissue, single cells or maybe
even just molecules are taken from a patient and examined. Thus this
would hopefully allow for less invasive means to be used to make or rule out
a diagnosis. Furthermore, in addition to making a diagnosis on a binary
level — either malignant or benign — appreciation of the molecular basis of
cancer may allow a better understanding of the behavior of various tumors
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to be used for prognosis or for better subgrouping of patients for appropriate
treatment.

6
The Thymosin (315 Study

INTRODUCTION:

Breast Cancer:
One in eight women will develop breast cancer in her lifetime. While
the incidence of this disease continues to gradually increase, mortality has
begun to fall [ 1, 9]. Thus fewer women are dying from breast cancer, while
more are living often comfortable and productive lives with the disease.
Though early detection — provided by the increased use of mammography
and the self-exam — combined with the wide acceptance of breast-sparing
surgery have reduced the death and disfigurement from this disease,
breast cancer still takes a significant toll. About 185,000 people will be
diagnosed with breast cancer this year, and about 45,000 will die from
breast cancer[ll.
While there are many histological subtypes of breast cancer, ductal
carcinoma is responsible for 80 percent of cases. The next most common
variant, lobular carcinoma is responsible for another 10 percent. There are
similarly many etiologies ascribed to breast cancer. As breast cancer is a
hormonally associated tumor, many of the risk factors relating to a
woman’s menstrual periods and pregnancy share a commonalty in that
they all result in prolonged exposure of the breast to estrogen. [10] Family
history is also notably a risk factor for breast cancer with about five to 10
percent of all cases and 25 percent of cases diagnosed before age 30
attributable to a familial syndrome such as the breast or breast-ovarian
cancer syndromes caused by mutation of BRCA1 or BRCA2[11].
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The molecular basis of breast cancer is not nearly as well understood
as it is for colorectal cancer (see below). Similarly, the multi-step
hypothesis is not well established. There are many benign histological
variations in breast tissue. For the most part, the clinical significance of
these changes lies in their ability to mimic early breast cancer by
presenting as a lump or a mammographic abnormality.

However, some

proliferative lesions seem to correlate with an increased risk of breast
cancer especially when cellular atypia is found[12]. It is unclear whether
breast cancer arises from areas of atypical hyperplasia directly, or
alternatively if atypical hyperplasia and breast cancer both result from a
common cause such as an inciting environmental agent or a hereditary
predisposition. In the breast, cancer can be found lurking in the ducts or
lobules as an in situ carcinoma. While this is generally thought of as a less
advanced form of the disease, it is unclear whether breast cancer is able to
proliferate only within the ducts and lobules before it acquires the ability to
invade through the basement membrane and infiltrate into the
parenchyma.
As far as the oncogenes and tumor suppressor genes involved in
breast cancer go, the gene known as erbB-2, HER-2, or neu is perhaps the
most extensively studied. Interestingly, this proto-oncogene, which is
related to the epithelial growth factor receptor (EGFR), is amplified in 10 to
30 percent of infiltrating ductal carcinomas and 60 percent of ductal
carcinoma in situ (DCIS) but is not amplified in benign breast disease[13].
Amplification of int-2, c-ras, c-myc, and cyclin D1 has also been found in
breast cancer. Germ line mutations in p53 have been associated with
breast cancer, and mutations in this tumor suppressor gene have also been
found in spontaneous breast cancer. Somatic mutations in the
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retinoblastoma tumor suppressor gene (Rb) have been found in breast
cancer as well. [14-16] As mentioned, BRCA1 and BRCA2 have been shown
to be involved in familial forms of breast cancer, yet somatic inactivation of
these genes is at most extremely rare in spontaneous breast cancer[17-19b
Stage of the disease — which involves tumor size, node status, and
the presence of distant metastasis — is a better prognostic indicator than is
histological subtype. Another factor in determining the prognosis is
presence of the estrogen receptor (ER) and the progesterone receptor (PR) in
the tumor cells. Loss of these receptors correlates with worse survival,
partly because it indicates that growth of the tumor is not at all hormone
mediated, and it precludes the effectiveness of endocrine therapies. The
search for better markers of clinical outcome is ongoing.

Growth fraction,

aneuploidy, the presence of enzymes such as cathepsin B, and genetic
alterations of oncogenes or tumor suppresser genes such as
erbB-2/neu/HER-2 or p53 have been suggested, although they are not widely
clinically utilized. [20]
Part of the surgical intervention for breast cancer involves a
dissection of the axillary lymph nodes. Procurement of the nodes in order
to stage the disease is essential for prognosis and planning therapy,
although it is possible that any therapeutic benefit may be replaced by a
nonsurgical modality[21]. A prognostic marker as good or better than
lymph node metastasis might replace the need for this procedure. The
expression level of a protein related to metastasis could conceivably provide
this necessary information.
Beside looking for a better prognostic marker, there are other reasons
why a better understanding of the alterations of protein expression in breast
cancer may be clinically relevant. As benign changes can present either

9
clinically or radiographically similarly to early breast cancer, it is
necessary to biopsy many lesions that turn out to be benign in order not to
miss treatable breast cancers. In addition to being invasive, this is
expensive. An alternative to open biopsy is fine needle aspiration for
cytology. Inaccuracy of this technique precludes it from preventing a biopsy
in many cases[22, 23].

Perhaps molecular analysis could increase the

sensitivity of this test.

Thymosin [515:
Beta thymosins are a family of closely related, highly polar five
kilodalton polypeptides. Thymosin (315, the newest addition to this family,
was recently uncovered in a search for proteins with increased expression
in motile as compared to poorly motile Dunning rat prostatic carcinoma
cell lines. The protein, which is 5300 Da, was designated thymosin (315
because of its approximately 60 percent homology with other members of
the beta thymosin family. Human thymosin (315 was found to be identical
in sequence to its rat counterpart. [24]
The beta thymosins are thought to play an integral role in
modulating the actin cytoskeleton. All vertebrates studied and some
invertebrates are known to contain one or often two beta thymosins[25]. The
precise role of any beta thymosin in regulating actin, however, is not well
described, nor is the need for multiple beta thymosins or the potential
differences in function between the members of this family fully
appreciated.
Thymosin (34 is the most abundant beta thymosin in most
mammalian tissue and is the best studied member of this family. Current
understanding is that thymosin (34 sequesters a large pool of monomeric

10
actin that is accessible to be released as needed for polymerization of actin
filaments[261. In some cells, such as platelets[27[ and neutrophils[281,
thymosin (34 can sequester the majority of actin monomers, while in other
cells its level is only sufficient to sequester a smaller fraction of the
unbound actin[29].
In vitro and in vivo experiments have demonstrated the role of
thymosin [34 as a passive actin monomer sequestering protein, i.e. its
function is mediated solely by altering the amount of available actin
monomers — it is not directly involved in actin polymerization, nor does it
otherwise affect the kinetics of that interaction[30]. As would be expected,
microinjection or overexpression of thymosin [34 in cells has been shown to
cause disassembly of actin stress fibers [31-33]. Similar results have been
shown for other beta thymosins such as thymosin j310[33, 34], thymosin [39,
and thymosin [3met9[35] confirming the role of the beta thymosins in
sequestering actin monomers. Similarly, thymosin [315 was shown to bind
monomeric actin and inhibit actin polymerization[24].
Recent data may dispute the notion that beta thymosins are simple
actin monomer binding proteins, and the role of the beta thymosins with
respect to actin may indeed be more complex. In contrast to previous
studies where large excesses of beta thymosins in cells were shown to
promote actin filament disassembly, a modest overexpression of thymosin
[310 mediated by cDNA transfection in the NIH3T3 cell line paradoxically
promoted actin filament assembly without changing the levels of other
actin binding proteins. The actin filaments that were seen appeared
thicker than normal and were clumped together. [29]
A low affinity interaction between the filamentous form of actin and
thymosin [34 has also been identified. When actin polymerizes in the setting
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of a high concentration of thymosin (34, thymosin (34 is found to be
associated with the actin filaments formed, which appear to self-associate
and twist around each other. Also, whereas low concentrations of
thymosin (34 cause a linear decrease in the amount of filamentous actin,
under certain conditions the relationship plateaus at high concentrations of
thymosin (34.[36]
Regardless of their precise role, the interaction of the beta thymosins
with the actin cytoskeleton suggests that they may be involved in important
actin-mediated functions such as motility, cell differentiation,
carcinogenesis, and metastasis.
In many cells the actin cytoskeleton is a dynamic structure.

In

addition to helping provide architecture to the cell, as is well described in
red blood cells[37, 38], it is now widely accepted that the constant
remodeling of the actin network within the cell is important in driving cell
locomotion. In fact, actin is necessary for cell movement in all but one of
the animal cells studied, the exception being nematode sperm cells, in
which another filamentous protein serves the role of actin[39].
Cell motility involves dramatic changes in the actin cytoskeleton
mediated by rapid polymerization and depolymerization of actin filaments.
The complex coordination required for cells to crawl or glide across a
substrate has been well studied and much of what is known is beyond the
scope of this text but is well reviewed elsewhere[39, 40]. In order for cell
movement to proceed, spatial and temporal control of the simultaneous
polymerization and depolymerization of filamentous actin, as well as
similar maintenance of the monomeric actin pool is of paramount
importance.
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Control of actin polymerization and depolymerization is achieved by
at least three mechanism: properties intrinsic to actin itself, the exchange
of adenine nucleotides by actin monomers, and the interaction of actin with
other proteins. The intrinsic polarity of actin filaments such that
elongation is relatively favored at one end is an example of the first type of
regulation. The fact that actin monomers bound to ATP are favored for
polymerization and that actin monomers bound to ADP are released by
filaments during depolymerization is an example of the second. The third
type of control is accomplished by the wide array of proteins broadly
classified under the term actin binding proteins or ABPs. The beta
thymosins, of course, are examples of ABPs. [41]
There are five major ways in which ABPs are thought to affect the
dynamics of actin polymerization and depolymerization:

1) ABPs can cap

the free ends of actin filaments to prevent elongation, 2) ABPs can suppress
the nucleation of new actin filaments, 3) ABPs can sever actin filaments
thus increasing the number of ends and hence facilitating
depolymerization, 4) one ABP, profilin, directly participates in the addition
of actin monomers to actin filaments thus promoting elongation, 5) ABPs
such as the beta thymosins can buffer the concentration of free monomers
such that elongation does not dramatically reduce the amount of available
actin monomers. [41, 42] The participation of ABPs in the regulation of cell
motility is reviewed elsewhere[30, 41, 42].
That actin should be involved in carcinogenesis and metastasis is
logical. Motility is essential in the complex series of events that compose
distant metastasis [43], Actin based motility may also be involved in the
spread of a non-metastatic tumor within the tissue of origin. The actin
cytoskeleton is known to have multiple physical linkages to membrane and
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adhesion complexes[37, 38], some of which have well studied associations
with neoplasia and metastasis. Direct evidence backing the crucial role of
actin in the development of the neoplastic and metastatic phenotypes
continues to mount. In many transformed or malignant cell types
disturbances or alterations in actin itself or in the actin binding proteins
has been demonstrated[43, 44].
The role of the beta thymosin family in cell motility is not well studied
despite the ample evidence that the actin cytoskeleton is of paramount
importance in mediating this function.

In the studies where increased

thymosin (310 expression ironically promoted actin filament assembly, it
was shown that the increased expression of thymosin (310 also promoted
cell spreading, chemotaxis, and the ability of the cells to heal a “wound” in
a monolayer[29]. Thymosin (315 also appears to positively regulate cell
motility as transfection of antisense thymosin (315 into motile rat prostatic
carcinoma lines impairs cell motility in a Boyden chamber apparatus,
while transfection of sense thymosin (315 increases the motility of poorly
motile cell lines [24].
Given the properties of the beta thymosins with respect to the actin
cytoskeleton, it would seem that they may be involved in cell differentiation,
carcinogenesis, and metastasis. While this has been studied, the function
of the beta thymosins in this respect is unclear. In some cell lines,
increased thymosin (34 protein or mRNA has been shown to correlate with
differentiation, while in others it has not[26]. Proliferating NIH3T3 cells
have increased thymosin (34 mRNA levels compared to quiescent cells [45].
Thymosin (310 also appears to be related to the process of programmed cell
death in that antisense thymosin (310 mRNA inhibits apoptosis mediated by
A23187 and TNF-a[34],
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In human tumors, thymosin (34 mRNA has been shown to be
increased in hairy cell leukemia, while it is reduced in some
lymphomas [46]. In one study, two out of three metastatic colorectal
carcinomas showed decreased thymosin (34 mRNA compared to
nonmetastatic tumors with the third metastatic tumor showing little
change[47]. Thymosin (310 mRNA levels are increased in renal cell
carcinomas[48, 49], and increased thymosin (310 expression was shown to
correlate with the metastatic potential of melanomas[50].
As thymosin (315 has only recently been described, it is less well
characterized. Its expression was shown to be increased in invasive human
prostate cancers at both the mRNA and protein level as compared to the
less invasive prostate cancers examined.

Immunostaining of human

prostate cancer cases also revealed a general correlation between Gleason
grade — a measure of differentiation — and thymosin (315 expression, with
high grade tumors (Gleason grade 8-10) showing increased staining
compared to low grade tumors (Gleason grade 2-5). [24]
The promising preliminary data from the prostate studies prompted
us to undertake a study of thymosin (315 expression in human breast tissue.
The aim was to determine the subcellular localization of thymosin (315 and
whether thymosin (315 expression is associated with malignant changes of
the breast epithelium. To do so, breast tissue representing a range of
conditions from normal to neoplastic was examined using a polyclonal
anti-thymosin (315 antibody.
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RESULTS:

Thymosin (315 is located diffusely throughout the cytoplasm but is excluded
from the nucleus
Paraffin-embedded tissue from both benign and malignant breast
lesions was stained by the immunofluorescence method in order to
determine the subcellular localization of thymosin (315 and the relative
specificity of the affinity-purified anti-thymosin (315 antibody. In all breast
epithelial cells, staining for thymosin (315 was located diffusely throughout
the cytoplasm and was excluded from the nucleus (Figure 1). The intensity
of the staining of breast epithelial cells varied from slide to slide and even
within the same slide. While the intensity of the staining was not formally
scored in the slides stained by the immunofluorescence method, it was
clear that there was at least one example for both benign and malignant
glands where there was intense staining, and at least one example for each
of staining that was not significantly greater than background. The anti¬
thymosin (315 antibody stained endothelial cells in addition to the breast
epithelial cells. Also, in some slides it seemed to stain more intensely in
myoepithelial cells (Figure 1), but this finding was not represented in all
the specimens. There was a minimal but noticeable background staining
in the stromal elements throughout all the slides examined as compared to
secondary antibody-only negative controls, which did not have any
detectable signal.
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Expression of thymosin (315 is increased in DCIS and invasive cancer
compared with benign breast epithelium
For ease of interpretation, the remainder of study was done using
conventional peroxidase-based staining and standard light microscopy.
Forty-three slides of surgical specimens obtained at Yale-New Haven
Hospital, representing a spectrum of breast lesions, were stained using the
anti-thymosin (315 antibody and visualized with a biotinylated secondary
antibody, peroxidase-linked avidin and diaminobenzidine substrate.
Twenty-one slides were from cases showing only benign changes, and 22
slides had a primary diagnosis of malignancy (6 of these showed only
ductal carcinoma in situ (DCIS) and 16 had infiltrating cancer). Many
slides contained tissue representing more than one diagnosis, however,
there were no malignant changes on any of the slides where the primary
diagnosis was benign and no infiltrating cancer on slides from cases with
the primary diagnosis of DCIS. All slides were from female patients, and
the average age of the patients was 43 for the benign slides and 59 for the
malignant slides.
As with the immunofluorescent slides, there was some minimal
background staining of the stroma. There were also variable levels of
thymosin (315 expression in the epithelial elements.

Each slide was

examined and scored by three independent observers. Staining was scored
on a scale from “0” (staining not greater than background) to “3+” (very
intense staining). Examples of the different scores are shown in Figure 2.
On each slide, normal glands, hyperplastic glands, DCIS, and
infiltrating cancer were given separate scores based on the average
intensity of staining of all the cells with the given diagnosis on the slide. A
score for the average staining of all the benign elements on each slide was
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also given. The three individual scores were compiled to give combined
scores on a scale from zero to nine. Table 1 shows a summary of the benign
cases including the diagnosis and overall score. Table 2 contains similar
data for the malignant cases, but in addition to the overall score of the
benign elements, it also includes scores for the DCIS and invasive cancer
regions on each slide. For the slides with infiltrating cancer, the status of
the axillary lymph nodes with respect to metastases, size of the resected
tumor, estrogen receptor (ER) and progesterone receptor (PR) status, and
ploidy of the tumor are shown.
A summary of all the data separated by diagnosis is provided in Table
3. The average score represents that for the combined elements for those
slides with a benign primary diagnosis, that for the DCIS on the DCIS
slides, and that for the infiltrating cancer on the slides with infiltrating
cancer. The score for each slide could be converted to a binary value of
either “positive” if it was greater than or equal to five, or “negative” if it was
less than five. The percent of slides in each diagnosis scored as “positive” is
also shown in Table 3. Distribution of the scores for the benign and
malignant cases is shown in Figure 3, illustrating the preponderance of
stronger staining in malignant epithelium than in benign epithelium.
To evaluate these data for significance, a contingency table was
constructed (Table 4). Calculation of the chi squared statistic shows a
statistically significant increase in the number of malignant slides scored
positive as compared with the benign slides (Fischer’s exact p-value =
0.0002). There were also more DCIS slides scored as positive (p = 0.0149)
and infiltrating cancer slides scored as positive (p = 0.0014) when these
were compared individually to the benign slides. The slides of tumor with
and without nodal metastasis were both more positive than the benign

18
slides when compared individually (p = 0.0329 and p =.0311 respectively).
Among all the slides, nine cases could be selected that allowed the
comparison between malignant cells and benign cells from the same
patient on the same slide. In this group, the malignant cells were scored
more positive than the adjacent benign cells (p = 0.0034).
No correlation was found between staining pattern and age, node
status, tumor size, ER status, PR status, or ploidy.
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DISCUSSION:

Thymosin [315, like other members of the beta thymosin family, is
known to bind actin monomers and is thought to be associated with cell
motility. Evidence that its expression is increased in human prostate
cancers, and that this increase appears to correlate with grade of the
disease suggests that it may mark metastatic potential[241. This study
suggests breast tissue may show similar properties; that increased
expression of thymosin [315 is associated with malignant changes of the
ductal epithelium.
Both ductal carcinoma in situ and infiltrating ductal carcinoma
contain more thymosin (315 than benign breast tissue of several diagnoses
such as fibroadenoma, sclerosing adenosis, and atypical hyperplasia.

This

increased expression can also be seen as significant when benign and
malignant cells on the same slide are compared, neutralizing all
confounding variables such as age that go along with the differences in the
patient populations between the group with benign and the group with
malignant breast disease.

Thus increased expression seems to be more a

feature of malignant changes as compared to benign changes in breast
tissue.
If indeed tumors progress from DCIS to nonmetastatic infiltrating
ductal carcinoma to metastatic breast cancer, it seems that the increase in
thymosin [315 expression can occur early in this process. Both DCIS and
node negative breast cancer have increased thymosin [315 expression in this
study indicating that upregulation of thymosin [315 may occur early in the
oncogenic pathway.
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This primary study is too small to assess an association between
metastasis and expression of thymosin (315 in a meaningful way.
Although, seven of eight tumors with nodal metastases at presentation
showed positive staining, four of four node negative cancers scored and five
of five in situ cancers scored were also positive. Thus while increased
expression of this protein may be related to motility, in breast cancer it is
not solely a feature of metastasis or even invasion.
In the breast, thymosin (315 expression distinguishes malignant
from benign lesions but possibly not metastatic from nonmetastatic tumors.
This might be different from the prostate model, where thymosin (315
expression was increased only in high grade and metastatic tumors.
Perhaps the greater motility mediated by increased thymosin (315 is utilized
by some intraepithelial and nonmetastatic breast cancers for spreading
within ducts or within the breast, whereas in the prostate it is only needed
for the ability to enter the blood vessels or lymphatics.
While it now seems clear, at least in two tissues, that alterations in
thymosin (315 expression occur with malignancy, it remains unclear
whether this change is involved in driving the transformation or is instead
a byproduct of the transformation itself. For instance, it is possible that
increased thymosin (315 expression either causes increased cell motility
through the sequestration of monomeric actin and hence the breakdown of
actin stress fibers, or that it is merely a marker of the increased cell
motility that the tumor has acquired through another mechanism. Other
studies will be required to make this determination.
In this study, levels of other ABPs or of other beta thymosins were not
examined. Thus it is unclear whether the increased expression of
thymosin (315 in breast cancer is unique or is common feature of related
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proteins. It seems that the beta thymosins are independently regulated as,
in the work with prostate, motility and malignancy were associated with
increased thymosin (315 but not with variations in the expression of
thymosin (34 or thymosin (310 in the cell lines or tissue samples studied[24].
It remains unknown whether this holds true for the breast.
In any case, the increased thymosin (315 in breast and prostate
malignancies gives more evidence to the logical assumption that the actin
cytoskeleton plays an important role in carcinogenesis whether as a
downstream effector of other changes or through “inside-out” signaling as
an initiator of the process.
In this study some malignant lesions stained weakly or moderately,
while some of the benign tissue appeared to have a strong staining pattern.
We are unsure of the significance of this observation. It is conceivable that
there is a wide variation in thymosin (315 expression within a given lesion.
While there are examples of benign tissue with increased expression and
malignant tissue with baseline expression, overall malignancy trended
toward increased thymosin (315 expression. Another explanation is that
there is indeed a level of expression that is specific for malignancy, but this
was hidden because the staining method employed here was not sensitive
enough to always distinguish between small gradations in the level of
protein within cells.
Finally, it is possible that increased levels are associated with
physiological epithelial remodeling, obscuring the changes associated with
malignancy. As the breast is an organ that undergoes continual
remodeling (associated with the menstrual cycle), it is not surprising to see
this motility-related protein expressed in benign tissue.
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The diagnostic utility of the increased thymosin (315 expression seen
in malignancy remains to be determined. This work represents a pilot
study, with insufficient numbers and follow-up to determine the
independent prognostic value of this marker.

Further work, including

production of monoclonal antibody, providing for more specific staining and
hopefully an increased ability to accurately quantitate expression, will be
required for rigorous testing of these findings and determination of the
value of this marker in prediction of metastasis.
Within breast epithelium thymosin (315 is localized to the cytoplasmic
compartment as is the case with thymosin [34 and thymosin (310(331. The
cytoplasmic location of the beta thymosins is consistent with their
association with the actin cytoskeleton. While myoepithelial cells may
contain increased levels of thymosin (315 compared to breast epithelial cells,
this seems to be an inconstant feature, and the significance of this is
unclear.
In summary, this study shows that thymosin (315 is contained within
the cytoplasm of breast epithelial cells, and that thymosin (315 expression in
increased in malignant as compared to benign breast tissue. Future
studies are needed to determine the precise role and prognostic value of
thymosin [315 in breast disease.
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The P120cas Study

INTRODUCTION:

Colorectal Cancer
Much like breast cancer, colorectal cancer is a problem of great
magnitude. About 135,000 people will be diagnosed with colorectal cancer,
and over 50,000 people will die from this disease in the United States this
year. It is the second most common cause of cancer death next to lung
cancer, and it is the second most common type of cancer in both women and
men.

Improved chemotherapy and screening has increased survival for

those with colorectal cancer since the 1970s. [1]

Similarly, increases in our

surgical knowledge allowing for sphincter-sparing surgery have increased
the quality of life for many with rectal cancer. Yet as the statistics indicate,
the problem of colorectal cancer is still very much with us.
The most significant risk factors of colorectal cancer are related to
diet and a wide variety of predisposing conditions. Of the predisposing
conditions there is inflammatory bowel disease and a host of hereditary
conditions that result in kindreds with increased incidences of colorectal
cancer[51]. In fact, up to about 10 percent of colorectal cancer probably
arises in the setting of a familial predisposition[52]. The list of hereditary
syndromes that can result in colorectal cancer is long and peppered with
many eponyms. What bears mentioning is that most of these syndromes
are characterized by polyposis, or the presence of multiple polyps in the
large bowel.[51] It is in these adenomatous polyps that cancer arises. This
is also the case with nonhereditary cases of colorectal cancer — the
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majority of cases are thought to arise from pre-existing adenomatous
polyps [53],
The fact that colorectal cancer often arises from polyps is part of what
makes this a useful model in which to study the progression of cancer. It is
held that colorectal cancer progresses from benign epithelium through a
series of histological changes including hyperproliferation of the
epithelium, development of a polyp, increases in dysplasia, and the
acquisition of villous or finger-like morphology. Conveniently, lesions at all
stages of this progression — from small adenomatous polyps of low
malignant potential to polyps with areas of severe dysplasia to cancers
arising from and still contained within a polyp to large metastatic
tumors — are accessible for study. [31
As previously indicated, it appears that colorectal cancer progresses
from a series of nonlethal genetic insults that accompany these histological
changes.

Benign polyps have alterations in tumor suppressor genes and

oncogenes but in general not as many of these changes as full-blown
cancers[3].

In specimens where cancer is seen with adjacent adenomatous

changes, it can be shown that the cancer is genetically derived from the
adenoma in that it has the same genetic changes but has at least one
additional change as well[54, 551.
APC, the gene mutated in the germ line of individuals with the
familial adenomatous polyposis syndrome, is lost in 35 to 60 percent of
sporadic colorectal tumors.
early adenomas.

This is the most common change in small,

Mutations in the ras genes occur in about 50 percent of

colorectal carcinomas and in a similar percentage of adenomas greater
than 1 cm suggesting that this change most commonly occurs at the early
adenoma stage. DCC, or the “deleted in colon cancer” gene, is located on
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the chromosomal region 18q, which is lost in 70 percent of carcinomas and
50 percent of late adenomas. The loss of 17p where p53 resides occurs in 75
percent of colorectal cancer but is rarely found in adenomas suggesting
that this change often occurs late in the transition from adenoma to
carcinoma. [52]
There are several potential clinical uses for molecular diagnostic
techniques in colorectal cancer. First, mortality from this disease will be
reduced by improved screening, which will allow detection of cancers and
adenomatous polyps at earlier stages. Right now, the only noninvasive
screening method widely used is the fecal occult blood test, which is
notoriously lacking in both specificity and sensitivity[56]. While cancers
can be directly visualized and polyps can be seen and removed by
colonoscopy or sigmoidoscopy, limiting the widespread use of these
procedures by first using noninvasive screening could lessen needless
expense and discomfort. The best known marker for colorectal cancer is
the blood level of the carcinoembryonic antigen (CEA), and although this
has proved useful in screening for recurrence of colorectal cancer, it has
not proven useful in screening for initial cases[57]. P53 mutations have
been detected in the stool of some patients with colorectal cancer but this too
has not yet proven useful for screening[58].
Another possible use for molecular diagnostic techniques is in
increasing the use of sphincter-sparing surgery for rectal cancer.

In colon

cancer it is often possible to take a wide margin of resection and thus limit
recurrence. In distal rectal cancer, however, it is often not possible to take
such a margin without compromising the anal sphincter and thus
necessitating a permanent colostomy. It is now generally accepted that a
margin of 2 cm is satisfactory, and this has allowed continence to be
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preserved for many patients[59-66]. Molecular assessment of surgical
margins may allow for less than 2 cm to be taken in some cases thus
affording a more comfortable survival for some patients.
Lastly, as with all types of cancer, prognostic information is
important both clinically and for the mental well-being of the patient. Right
now the best information is provided by the depth of invasion of the tumor
and the presence or absence of both lymph node and distant metastasis.
Other histopathological data that can be used for prognosis includes the
grade of the tumor, the presence of invasion into the pericolic fat, and the
presence of invasion into lymphovascular structures.[51] A better
understanding of the alterations in protein expression of colorectal
carcinomas may allow for better prognosis, better assessment of surgical
margins, or better screening.

P120cas:
A 120 kDa cadherin-associated src substrate, rather unglamoursly
known as pl20cas, was discovered as a protein whose tyrosine
phosphorylation in chicken cells expressing mutants of c-src tightly
correlated with phenotypic transformation[67]. It was shown that pl20cas
was also tyrosine phosphorylated when quiescent NIH3T3 cells were
stimulated with growth factors such as epidermal growth factor (EGF),
platelet-derived growth factor (PDGF), and colony-stimulating factor 1
(CSF-1), thus placing this protein as a downstream effector of mitogeninduced signaling pathways [68]. Later research linked this protein both
phylogenetically and physically with adhesion associated molecules.
Though it was known to be membrane associated from its discovery,
the first evidence linking pl20cas with cell adhesion came when cloning of
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the gene identified 11 copies of a characteristic 42 amino acid repeat placing
it in the arm family of proteins . The arm family — originally described for
the Drosophila segment polarity gene product armadillo — is known to
contain the catenins [3-catenin and plakoglobin (y-catenin).[69, 70] Later co¬
localization and immunoprecipitation experiments confirmed the
hypothesis that pl20cas functions as part of the adhesion complex that
contains the cadherins and the catenins[71, 72].
The cadherins are a superfamily of transmembrane glycoproteins
that connect cells by calcium-dependent homotypic interactions between
their extracellular domains. Within this superfamily is a subgroup called
the classic cadherins — such as E-cadherin, N-cadherin and P-cadherin —
that exist as groups of dimers on each cell and mediate the formation of
adherens junctions (belt desmosomes) between cells. E-cadherin, the most
prevalent cadherin in epithelial cells, is the best studied member of the
group.

Proper clustering and functioning of E-cadherin depends on

interactions of its cytoplasmic domain. [73, 74] The catenins are a group of
molecules that bind to the cytoplasmic tail of E-cadherin and are required
for cell-cell adhesion[75, 76].
The catenins include [3-catenin, plakoglobin, a-catenin, and p!20cas.
As mentioned [3-catenin and plakoglobin are two members of the arm
family; they are 65 percent homologous with one another. They associate
with the cytoplasmic region of E-cadherin in a mutually exclusive
relationship. The proximity of the binding sites for (3-catenin and
plakoglobin on E-cadherin probably prevents the binding of both proteins to
a single molecule of E-cadherin, though it is possible for a dimer of Ecadherin to be bound to both proteins. The way in which E-cadherin selects
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its binding partner is unknown, P120cas can also bind to the cytoplasmic
tail of E-cadherin.[75]
Either [3-catenin or plakoglobin can serve as a bridge between Ecadherin and a-catenin. Closely related to the actin binding protein
vinculin, a-catenin is thought to link the complex to the actin cytoskeleton
either by directly binding actin [77] or by binding a-actinin[78]. Both (3catenin and plakoglobin bind a-catenin and link it to the cadherin complex,
though a-catenin does not itself bind E-cadherin. P120cas does not bind
directly to a-catenin. [79, 80]
Defective interactions of any member of the cadherin complex result
in failure of cell-cell adhesion. As will be seen, loss or defects in Ecadherin, a-catenin, [3-catenin, plakoglobin or pl20cas can result in loss of
the epithelial phenotype. Tyrosine phosphorylation of [3-catenin,
plakoglobin and p!20cas may also function in negative regulation of the
complex and the loss of adhesive properties [81, 82].
Another interesting interaction of the catenins, especially in the
colorectal cancer model, is that of [3-catenin and plakoglobin with the
adenomatous polyposis coli gene product (APC). APC is a tumor
suppressor gene discovered as the gene mutated in the familial syndrome
characterized by the development of hundreds of neoplastic polyps in the
colon, which if left unresected will inevitably develop a cancer at a very
early age[83]. As previously mentioned, APC is also found to be mutated in
a large percent of spontaneous colon cancers, and this change is considered
one of the first steps in colon carcinogenesis [52].
Interestingly enough, APC is also known to have arm repeats,
although its gene product localizes to the cytoplasm not the membrane[69].
Plakoglobin and [3-catenin bind to APC but cannot bind APC and E-
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cadherin simultaneously. Although the significance of this is unknown, it
is thought that APC downregulates (3-catenin and plakoglobin, and that the
interaction between (3-catenin or plakoglobin and APC may be involved in
contact inhibition of growth.[84] It has been shown that p!20cas does not
interact with APC [80].
In the catenin family, [3-catenin and plakoglobin have no known
alternative spliced forms whereas a second isoform has been identified for
a-catenin[85]. P120cas, on the other hand, has several isoforms. Variation
is seen between different types of cells in terms of isoform expression, and
certain isoforms may correlate with differentiation[86]. The significance of
this is still unknown.
The idea that adhesion-related molecules should play an important
role in carcinogenesis and metastasis is an old one. Pathologists have long
observed that in carcinomas there is a loss of the normal epithelial
morphology of the tissue of origin or a disorganization of cell-cell adhesion.
This is especially prominent at the borders of a tumor where
dedifferentiated cells are seen to infiltrate into the surrounding tissue[87,
88]. The concept that down modulation of cell-cell adhesion molecules is
responsible for mediating the increased mobility and invasiveness needed
for the progression of carcinomas was proposed about 50 years ago[89-91].
For metastasis, it seems that downregulation of cell-cell adhesion
molecules should be especially important. It is known that metastasis is a
multi-step process involving loss of cell-cell adhesion, loss of cell-substrate
adhesion, migration into the lymphatics or bloodstream, homing to a new
site, and attachment to that new site.
Cell adhesion molecules are now known to function in signal
transduction, and thus in addition to mediating functions such as adhesion
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and motility, they may be involved in other processes linked to
carcinogenesis and metastasis such as growth, apoptosis, and gene
expression.

Furthermore, these molecules are involved in effecting

differentiation by mediating such processes as compaction, transition from
a mesenchymal to an epithelial morphology, and acquisition of normal
tissue architecture — processes that seem to be reversed in cancer. [92]
The cadherin complex is of paramount importance for cell-cell
adhesion. All cell types that form solid tissues express cadherins . In
general cells that express less cadherin complex molecules are less
adhesive. Inactivation of other molecules of cell-cell adhesion has little
effect on the cell so long as the cadherin complex is intact. The cadherin
complex molecules are also generally associated with an epithelial versus a
fibroblastic morphology. Furthermore, the cadherin complex is known to
be associated with the gene products of several classic oncogenes such as
src, yes and lyn.[74]
For the above reasons, it is not unreasonable to think that the
cadherin complex molecules would be involved in cancer. And in fact, it is
known that alterations in E-cadherin, a-catenin, (3-catenin, plakoglobin or
p!20cas can mediate the lack of adhesion and increased invasiveness or
metastasis of many types of cell lines or tumors. As this is well described
elsewhere[73, 93, 94], only those examples that relate to either pl20cas or
colorectal cancer will be reviewed.
While less well characterized than other members of the E-cadherin
complex, alterations in pl20cas have been shown in cancer. As mentioned
above, p!20cas was shown to have heterogeneous expression with isoform
variation between cancer cell lines[86].

In a ras transformed human

mammary cell line, tyrosine phosphorylation of p!20cas and [3-catenin was
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noted to correspond with less developed adherens-type junctions between
cells but increased focal adhesions. In these same cells increased pl20cas
was detected on E-cadherin, but (3-catenin was notably absent from the
complex[821.
In a study involving human bladder cancers about one third of the
tumors showed a heterogeneous staining pattern when examined with a
monoclonal antibody that recognizes all known isoforms of pl20cas, with
another six percent of the tumors showing total loss of pl20cas staining,
and the remainder showing a staining pattern indistinguishable from
normal urothelium. The pl20cas staining pattern in the bladder cancer
study correlated with staining for E-cadherin, though interestingly there
were a couple of cases in which there was complete loss E-cadherin
expression with heterogeneous staining for pl20cas seen at the membrane
begging the question of where the pl20cas was binding. The loss of staining
for pl20cas also correlated with worse stage, grade and survival, although
as far as survival is concerned the correlation between loss of pl20cas and
poor survival was less strong than that seen for (3-catenin, a-catenin and Ecadherin.[95]
In invasive ductal carcinoma of the breast, the breakdown was even
with about one third of tumors showing each normal, heterogeneous, and
complete loss staining patterns for pl20cas in one study. In a 40 X field
selected as having the least staining, complete loss of pl20cas expression
was seen in about two thirds of the same breast tumors. Paradoxically, loss
or alteration of p!20cas was correlated with tumors that had not
metastasized to the lymph nodes. [96]
As is the case with other cancers, the cadherin complex molecules
seem to play an important role in colorectal carcinoma. E-cadherin, [3-
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catenin, oc-catenin and pl20cas have each been examined with regard to
colorectal cancer using either cell lines or human tissue specimens.

The

data regarding each molecule’s part in colorectal carcinoma will be
discussed separately below.
E-cadherin’s relation to cell-cell adhesion, invasion, and metastasis
has been extensively explored using colorectal cancer cell lines, and the
data are all in concordance. Loss of E-cadherin in these cell lines
correlates with invasion[97-100]. In those cell lines in which E-cadherin is
expressed, monoclonal antibodies have been used to block that expression
resulting in increased invasiveness [99] as well as inhibition of cell-cell
adhesion and loss of glandular differentiation[101]. Transfection of Ecadherin into deficient cell lines resulted in increased cell-cell adhesion,
increased epithelial morphology, decreased motility, decreased
invasiveness and ability to form metastases in a host animal, decreased
growth rate, and interestingly decreased secretion of a protease[97, 100].
Cell lines implanted in animals showed decreased E-cadherin expression
compared to the same cell lines growing in vitro indicating that E-cadherin
may be transiently regulated in colorectal cancer[98, 102].
Human pathological specimens have also been used to examine Ecadherin in colorectal cancer. Areas of architectural atypia in colorectal
carcinoma were often found to have loss of E-cadherin staining[103, 104].
Membranous E-cadherin staining was also frequently found to be lost in
adenomatous polyps that were greater than one centimeter, high grade,
and with villous histology[104].
In general, metastatic foci of tumor had loss of E-cadherin
expression[103, 104]. Interestingly, in some studies, many metastases that
were found to have complete loss of E-cadherin originated from primary
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tumors with strong E-cadherin staining[103, 104], however, one study found
no striking differences in expression between lymphatic and hematogenous
metastases compared with their primary tumors[105].

Surprisingly one

paper reports that in tumors where cells could be visualized inside a
vascular compartment, the intravascular component stained at least as
intensely for E-cadherin compared to the extravascular component, and in
no instance was there stronger E-cadherin expression in the tumor seen
outside the vessel than was seen in the intravascular tumor cells[106].
E-cadherin expression has been shown to correlate inversely with
grade[103, 104, 107]. One author reports that E-cadherin expression
correlates with stage, such that low stage tumors — Dukes stage A and B
(American Joint Committee on Cancer (AJCC) stage I and ID — have
more E-cadherin expression than high stage tumors — Dukes stage C
(AJCC stage III and IV)[103], Other studies could not find a correlation
between E-cadherin expression and stage[104, 107], Loss of E-cadherin
expression in colorectal carcinoma was reported to correlate with worse
survival in one study[108].
Alterations of a-catenin expression in colorectal carcinomas have
been detected as well. In one paper, three of five poorly differentiated
colorectal cancer cell lines expressed E-cadherin, with two of these three
actually having increased levels. These three cell lines were found to be
deficient in a-catenin. Transfection of a-catenin into one of these deficient
cell lines gave rise to cells that had increased calcium-dependent cell-cell
adhesion and decreased migration on collagen compared to the parent
cells.[109]
Another paper examined deficiencies of the cadherin-catenin
complex in relation to morphology and invasion. Of the colorectal cell lines
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examined, those with an epithelial morphology were not invasive into
embryonic chick hearts, while all but one with a round cell morphology
were invasive. The cell lines with a round cell morphology were either
deficient in E-cadherin or a-catenin. All the cell lines in this study
expressed (3-catenin. Interestingly, all three cell lines that were deficient in
a-catenin were derived from cell lines that originally had an epithelial
morphology — one spontaneously emerged after several passages and two
were created by transformation with the neo oncogene. [110]
The finding that a-catenin expression is lost in some colorectal
cancer cell lines carries over to human colorectal cancer specimens.
Reduced a-catenin was seen in 80 percent of human colon cancers in one
study with complete loss in 75 percent of the cases with reduced
expression[lll]. In another paper, reduction of a-catenin expression
seemed to correlate better with metastases to lymph nodes or to the liver
than reduction of E-cadherin expression[112].
Only one study has examined [3-catenin’s role in colorectal
carcinoma. In this paper, [3-catenin was found to have reduced expression
in half of the colorectal cancers examined. In 71 percent of the cases,
expression of E-cadherin correlated with the expression of [3-catenin, while
in the remainder there was normal E-cadherin but reduced [3-catenin.
Loss of [3-catenin also correlated with high grade tumors. [113]
There is one paper in the literature that looked at pl2Qcas in
colorectal cancer. In this series of 13 tumors, four had greater or equal to
80 percent membrane staining of pl20cas (normal), six had between 10 to 80
percent staining (heterogeneous), and three had less than 10 percent
expression (complete loss). There seemed to be a general trend between
pl20cas expression and E-cadherin expression, although there was not a
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significant correlation. There was a correlation between loss of p!20cas
and larger tumor size when the group of normal expressors was compared
to the combined heterogeneous and complete loss groups. No correlation
could be found with either distant metastasis or metastasis to the lymph
nodes in this small group. [114]
Given the ample evidence that alteration of the cadherin complex
molecules is important in colorectal carcinogenesis and metastasis and the
relative paucity of knowledge about the role of pl20cas in this model, it
would seem reasonable to further explore the expression of pl20cas in
human colorectal carcinomas. A larger study of pl20cas expression in
human colorectal carcinoma than the one published would not only
confirm the data already presented there, but could also possibly find
clinicopathological correlations — such as with metastasis or survival —
that the smaller study might have missed. Given the relation of loss of
pl20cas expression with high grade, high stage, and decreased survival in
bladder cancer as well as the paradoxical relationship between increased
p!20cas expression and metastasis to lymph nodes in breast cancer, it
would be reasonable to expect to find a correlation with alteration in p!20cas
expression and these variables in colorectal cancer.
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RESULTS:

Many colon cancers show loss of pl20cas staining compared to normal
colonic epithelium

Paraffin-embedded slides from blocks selected to contain the junction
between a colorectal cancer and benign epithelium were stained using a
monoclonal antibody directed against pl20cas. For the pl20cas study, the
immunofluorescence method was used throughout, as it was easier to
quantify the level of expression when the clear membrane staining pattern
of pl20cas could be appreciated. In the vast majority of slides, the tumor
could be compared with an adjacent area of normal colonic epithelium that
served as an internal control of pl20cas staining. The normal colonic
epithelium uniformly stained strongly for p!20cas in a typical membranous
pattern (Figure 4). In two slides there was no staining seen on the slide
either in the tumor or in the control regions, and these were not scored.
There were other slides in which only benign tissue was seen on the slide,
and these also could not be included in the analysis.
The expression of pl20cas in the tumors was quantifiable by the
approximate percentage of cell membranes in which staining was seen.
The 45 slides containing tumor were scored as described above. Briefly,
both the overall staining of the tumor as seen on each slide and a 40 X field
that represented the area of the tumor with the least staining were scored.
The scoring system used was “+” for greater than 90 percent,
between 50 and 90 percent, “+/-

for

for between 10 and 50 percent, and

for

less than 10 percent expression. Examples for each score are shown in
Figure 5. The intensity of the staining is not reflected in the scoring system
despite the fact that the tumors on the whole had less intense staining —
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even when greater than 90 percent of the cell membranes stained — than
the adjacent normal tissue (Figure 4). The scoring of the 45 slides and the
clinicopathological data from each patient is shown in Tables 5 and 6.
Interestingly, in one case two separate slides from the same patient
were unintentionally stained and scored. In one section, the staining was
scored as less than 10 percent, while in the other there was between 50 and
90 percent pl20cas expression in the overall tumor as well as in the tumor
area with the least staining seen on that slide. While it is impossible to say
for sure, due to the large size of colorectal tumors, it is conceivable that one
large area of the tumor had complete loss of pl20cas accounting for the
absent expression seen in the one cut, while in another large area there
was much less pronounced loss of pl20cas. The analysis was constructed
as to be based on the reading of one slide for each tumor, despite the fact
that colorectal tumors are much larger than one slide, and that an
individual slide may not be representative of an entire tumor. For this
reason, the two slides mentioned above were treated as if they were two
separate cases with the same clinicopathological data.
It is worth mentioning that an adenomatous polyps with variable
pl20cas expression was incidentally appreciated on one of the slides not
considered in this study because of the absence of any malignant histology.
There seemed to be absent staining in areas of significant dysplasia (Figure
4). The possibility that pl20cas may be lost in dysplastic polyps as well as in
malignancy was not further studied.
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Loss of greater than 50 percent of pl20cas staining correlates with larger
tumor size compared with loss of less than 50 percent
When the tumors were divided into two groups according to their
overall expression of pl20cas by whether greater than or less than 50
percent of the cell membranes stained, there was a significant difference in
the size of the tumors between the two groups (p = 0.0120). The mean tumor
size in the group with less than 50 percent pl20cas staining was 6.38 cm,
and the mean in the group with greater than 50 percent staining was 4.24
cm (Figure 6).

Complete loss of pl20cas in a high power field representing the area of the
tumor with the least staining correlates with metastasis
Metastatic spread of colorectal primaries correlates with decreased
expression of pl20cas. When the tumors were divided into two groups
based on whether or not a 40 X field could be found in which there was
complete loss of pl20cas — less than 10 percent of membrane staining —
two significant correlations with metastasis could be appreciated. First,
complete loss of pl20cas staining in a 40 X field correlates with AJCC stage
III or IV disease, i.e. cancer that had metastasized to either the lymph
nodes or a distant organ (p = 0.0470). The distribution of cases by stage for
tumors with or without an area of complete loss of pl20cas expression can
be seen in Figure 7. The tumors with an area of complete loss of pl20cas
can be seen to have a higher proportion of advanced stage disease than is
the case for the tumors without an area of complete loss. A contingency
table constructed from these data is shown in Table 7.
Not surprisingly, complete loss of pl20cas expression found in a 40 X
field also correlates with lymph node metastasis alone (p - 0.0426). The
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distribution of the “worst” scores for node negative and node positive tumors
showing the high proportion of node positive cancers with an area of
complete loss of pl20cas expression can be seen in Figure 8. The
corresponding contingency table is also shown (Table 8). It bears
mentioning that while the vast majority of tumors with an area of complete
loss of pl20cas expression were metastatic by either of these two measures,
the majority of metastatic tumors did not have a least staining region with
complete loss of pl20cas expression.

Loss of greater than 50 percent of pl20cas staining in a high power field
correlates with the presence of histologically observed lymphovascular
invasion
Alteration of pl2Qcas expression also correlates with another sign of
invasiveness. For each of the 45 slides, the absence or presence of invasion
into a vascular or lymphatic structure was determined by reviewing the
pathology report from each resection.

In 19 tumors, such invasion was

noted. Greater than 50 percent loss of pl20cas expression in the tumor area
that stained the least correlates with the presence of histologically identified
lymphovascular invasion (p = 0.0156). The distribution of “worst” scores
separated by the presence or absence of lymphovascular invasion is shown
in Figure 9. Most of the cases with lymphovascular invasion were scored
as “+/- -” or “-” for their least staining area, whereas most of the cases
without such invasion were given a “worst” score of
table of these data can be seen as Table 9.

The contingency
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Greater than 50 percent loss of p!20cas staining in the tumor overall and
complete loss of p!20cas in an area the size of a high power field both
correlate with poor survival and shorter recurrence-free survival

Patient follow-up data for each patient were obtained from the YaleNew Haven Tumor Registry. From this source, a date that the patient was
last seen, as well as the status of the patient as either alive or dead could be
used to generate a survival analysis. Loss of 50 percent of pl20cas
expression on the entire portion of tumor seen on a single slide correlates
with worse survival under this analysis (Mantel-Cox logrank p-value =
0.0126). A Kaplan-Meier life table analysis of this association is shown in
Figure 10. There was also a significant correlation between complete loss of
pl20cas in the section of the slide that stained the least with poor survival
(p - 0.0162). This also can be seen in Figure 10.
Reviewing the Yale-New Haven Hospital pathology database, the
presence or absence of pathologically documented tumor recurrence along
with the date of the diagnosis could be determined if the diagnosis was
made at this hospital. As seen in Table 6, four patients had such a
recurrence representing five slides in this analysis.

In all cases, the

recurrence was metastatic as opposed to local.
Two points on these data should be made. In one patient, the tumor
that was scored was a local recurrence of a previous colorectal tumor. This
patient is now alive and disease free. As it cannot be determined from these
data whether the expression of pl20cas in the initial tumor would have been
the same as in this recurrence, for the purpose of analysis this tumor was
considered as if it were the first presentation of the disease. Thus this
tumor is considered to have no recurrences, and both survival and diseasefree survival are calculated from the date of the second operation. In

41
another patient, the colorectal tumor that was scored appeared about 20
years after an operation for another colorectal cancer. As this is well
beyond the time in which a local recurrence would be expected, this case is
treated as a second primary. As seen in Table 6, this patient is also alive
and disease free.
The length of recurrence-free survival could be generated from the
data mentioned above. As with overall survival, shorter recurrence-free
survival correlates with loss of greater than 50 percent of pl20cas
expression overall (p = 0.0313) and complete loss of pl20cas in an area the
size of a high power field (p = 0.0369). The Kaplan-Meier life table analyses
are shown in Figure 11.
As loss of pl20cas expression correlates with advanced stage, and
stage of colorectal cancer is a good prognostic indicator, it would seem that
any correlation between loss of pl20cas and survival or recurrence-free
survival would be based on the association between loss of pl20cas and
stage. It should be noted that advanced stage — AJCC Stage III and IV
disease — did not correlate with either worse survival or disease-free
survival (p = 0.0644 and p = 0.0911 respectively), although as would be
expected general trends were seen. Similarly correlations were not found
between survival or recurrence-free survival and lymph node status (p =
0.0549 and p = 0.0770), nor were they found between survival or recurrencefree survival and lymphovascular invasion (p = 0.5469 and p = 0.2361). The
relatively small sample size precluded the assessment of the true
independent predictive value of the overall or “worst” pl20cas expression.

Other possible associations were examined but could not be found.
The expression of pl20cas did not correlate with either patient age or
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gender. Nor did it correlate with the location of the tumor within the large
intestine (right colon, left colon, sigmoid or rectum). An association was
similarly not found between p!20cas expression and tumor grade or
between loss of p!20cas and mucinous or signet ring features as
documented on the pathology report. P120cas expression was not found to
correlate with the presence of a pathologically documented distant
metastasis at the time of operation, the occurrence of a pathologically
documented metastasis found in the follow-up period subsequent to the
operation, or the occurrence of a pathologically documented distant
metastasis found at either of these times.
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DISCUSSION:

P120cas is a member of the cell-cell adhesion complex that anchors
epithelial cells together through the homotypic binding of E-cadherin. It is
known that cells without this anchorage are usually more motile. In
cancer, when the proteins of the cadherin complex are lost the result is a
more metastatic phenotype[73]. This study shows that loss of pl20cas
expression is a common feature in colorectal malignancy, and that cancers
with pl20cas loss are more likely to be large, to be invasive, and to correlate
with poor survival of the patient.
In this study, tumors were scored for pl20cas expression in two
ways. One score was based on the percent of cell membranes staining for
p!20cas in the tumor seen on the entirety of one pathological slide. The
other score was based on the percentage of cell membranes staining for
pl20cas in an area of the tumor the size of a 40 X field selected as having the
least expression. It should be noted that the correlation between loss of
p!20cas expression and large tumor size was made using the “overall”
score, while the associations between loss of pl20cas expression and more
invasive tumors were made using the “worst” score. The correlations with
outcome could be made using both scores.
The data presented here confirm the results of a previous study
showing that alteration of pl20cas expression is a frequent event in
colorectal carcinoma[114]. Our study, however found a smaller percentage
of tumors that had only 10 percent or less pl20cas staining (two out of 45
slides or four percent versus three of 13 or 23 percent). The fraction of
tumors with normal staining — greater than 90 percent in our study and
greater than 80 percent in theirs — was roughly the same (12 of 45 or 27
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percent versus four of 13 or 31 percent). The percentage scored as
heterogeneous — between 90 and 10 percent staining in our study and
between 80 and 10 percent in theirs — was close with the difference
accounting for the smaller number scored for complete loss in our study (31
of 45 slides or 69 percent versus six of 13 or 46 percent).
Our data also confirm the result that loss of pl20cas expression
correlates with large tumor size. As our results are drawn from a series of
44 tumors compared to 13 in the previous study, additional weight is given
to these findings. In our study, the correlation between tumor size and loss
of pl20cas expression was made using the overall expression of pl20cas by
comparing tumors with less than 50 percent expression against those with
greater than 50 percent staining.
The additional patients and the use of the “worst” scores allowed us to
find correlations that the previous study could not. Our study found that
loss of pl20cas expression is associated with invasion in three ways.
Complete loss of pl20cas expression in a 40 X field correlates with both
lymph node metastasis and higher stage (AJCC Stage III or IV). Loss of
greater than 50 percent pl2Qcas expression in the area of the tumor with
the least staining also correlates with invasion of the lymphovascular
structures as seen histopathologically.
The correlations with stage and nodal status are almost identical.
The first analysis compares the group of tumors that had metastasized to
the lymph nodes versus those that had not. The second analysis looks at
AJCC Stage III tumors (those that are metastatic to lymph nodes but
without distant metastasis) and Stage IV tumors (those that have distant
metastases) compared to lower stage tumors. This switches the one tumor
in our series with pathologically documented distant metastasis at the time

45
of operation but without positive lymph nodes (AJCC Stage IV but negative
lymph nodes) from the “nonmetastatic” to the “metastatic” group.
The third correlation compares a histopathological feature associated
with metastatic behavior to pl20cas expression in the tumor area that
stained the least. By scanning Table 5, it can be seen that the presence of
lymphovascular invasion seems to be associated with actual metastasis, but
that some of the metastatic tumors were not seen to be invasive into
lymphovascular structures and similarly some tumors that were seen to
invade into lymphovascular structures were not metastatic. A formal
analysis would show the predicted result, lymphovascular invasion is
significantly associated with AJCC Stage III and IV disease (p - 0.0023),
lymph node invasion (p = 0.0013), the presence of pathologically documented
distant metastasis at the time of operation (p = 0.0243), and the occurrence
of a pathologically documented distant metastasis found either at the time
of the operation or in the follow-up period (p = 0.0067). Thus the fact that
loss of pl20cas expression correlates with lymphovascular invasion as seen
histologically is further proof that loss of pl20cas is associated with
metastasis and invasion in colorectal carcinomas.
In this study the majority of metastatic tumors were not observed to
have an area of complete loss of pl20cas. In all but one case, however, only
one section was examined despite the large size of colorectal tumors. In the
one case in which two slides were examined, which happened to be a case
with metastatic disease, only one of the slides revealed an area with less
than 10 percent expression of pl20cas. In order to more accurately
comment on regional loss of pl20cas in a large tumor, multiple slides
should be examined. If this were done, it may have revealed areas of loss in
the metastatic tumors where none were found. It thus may be the case that
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focal complete loss of pl20cas is essential for metastasis, or that there are
other mechanisms equally capable of mediating metastatic behavior.
If loss of p!20cas expression is seen as a marker for impaired
function of the cadherin cell-cell adhesion complex in which p!20cas
functions, then it is no surprise that such loss would correlate with
metastasis in colorectal cancer.

Metastasis in colorectal carcinomas was

found to correlate with loss of other proteins involved the cadherin
complex — E-cadherin in one study[103] and a-catenin[112] in another.
Loss of pl20cas has also been shown to correlate with metastasis in bladder
cancers[95], although interestingly it correlated inversely with metastasis
in a study of breast cancers[96]. Our finding is consistent with the
multitude of studies that have shown that loss of function of the E-cadherin
complex causes decreased cell-cell adhesion as well as increased motility
and invasiveness. Furthermore, this finding is in line with the hypothesis
that loss of cadherin-mediated cell-cell adhesion can cause
dedifferentiation or activation of oncogenic pathways and serves as
additional evidence in its support.
As the exact function of pl20cas within the E-cadherin complex is not
understood, the significance of these findings cannot fully be appreciated.
For instance, it is not known whether loss of p!20cas from the cadherin
complex would be expected to directly cause loss of adhesion and
metastasis. It may be that the loss of p!20cas seen in this study represents
an underlying dysfunction of the cadherin complex and is not a primary
event in causing the loss of adhesion. As E-cadherin expression was not
analyzed in this study, it cannot be said with certainty that loss of pl20cas is
not simply a marker for loss of E-cadherin at the membrane and hence loss
of a site for p!20cas to bind. However, the bladder cancer study — which
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found normal pl20cas expression at the membrane in some cases without
any E-cadherin expression — indicates that loss of pl20cas and loss of Ecadherin, though associated, can be two distinct events [95]. Whether any of
the changes in the cell-cell adhesion complex are primary events in
achieving the metastatic phenotype or are downstream effects of other such
changes is not known. It is also unclear why if loss of these molecules is
associated with metastasis, they may be lost in highly dysplastic but benign
polyps as is the case for E-cadherin[104] and may be the case for pl20cas.
An explanation as to why metastasis should only correlate with loss
of pl20cas expression as determined by the “worst” score, whereas tumor
size only correlates with loss of pl20cas as determined by the “overall” score
can be offered. Metastasis to the lymph nodes or elsewhere in the body is a
complex process, but each metastatic depot could conceivably originate
from one cell that detaches from the primary tumor. In other words if one
of the many cells in a tumor is able to successfully complete the steps
required in order for metastasis to succeed — including detachment from
the primary tumor, invasion through the stroma, invasion into the
lymphatics or blood stream, travel through the lymphatics or blood stream,
migration from the lymphatics or blood stream, attachment to a distant
site, and growth at the new site — then a metastatic tumor can form. Thus
if only a small area loses function of the cell-cell adhesion complex, a cell
from that one area may be able to metastasize.
In contrast, in order for a tumor to grow to a large size, it may
require the tumor to be composed of a dominant cell line with unregulated
growth. As it is known that the E-cadherin complex is involved in signal
transduction, it is conceivable that contacts with other cells may be
transmitted into downregulation of growth through this complex. If it is
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the case that function of the cell-cell adhesion complex in which pl20cas
participates is required in the contact inhibition of growth, then loss of this
function may promote uncontrolled growth. Thus loss of function of the
cadherin cell-cell adhesion complex in large areas of the tumor may be
associated with greater tumor size.
The fact that loss of pl20cas expression should correlate with both
survival and recurrence-free survival is consistent with the many of the
functions of pl20cas and the cadherin cell-cell adhesion complex in which
it participates. Survival should be based on numerous properties of the
tumor including its capability to metastasize, its state of dedifferentiation,
and its capacity for unregulated growth. What is interesting is that in this
study survival and recurrence-free survival were significantly associated
with loss of pl20cas expression but not with stage, lymph node metastasis,
or lymphovascular invasion. Also, survival correlates with both the
“overall” and the “worst” scores.
The sample size and limited follow-up time in this study preclude
any meaningful analysis of the independent predictive value of pl2Qcas
expression on survival or disease-free survival. Nevertheless, the fact that
p!20cas expression as quantitated by both the “overall” and “worst” scores is
associated with survival and tumor-free survival more strongly than stage,
lymph node metastasis, or lymphovascular invasion suggests that it may
indeed have such independent predictive value. The predictive value of
pl20cas expression on survival in relation to other cadherin complex
proteins remains to be seen. In bladder cancer, it has been shown that
expression of E-cadherin, a-catenin, and (3-catenin are better predictors of
survival than is expression of p!20cas[951.
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In summary, this study confirms the results of a much smaller
study that loss of p!20cas expression is a common event in colorectal
carcinoma and that such loss correlates with larger tumors.

The current

study furthers these results by showing that loss of p!20cas is related to
metastasis in colorectal cancers, and that loss of pl20cas predicts a poor
survival. Further studies will be needed to determine if loss of pl20cas is a
cause of increased invasiveness or if it simply represents poor function of
the cell-cell adhesion complex in which it functions. Additional studies
will also be needed to determine whether loss of pl20cas is truly an
independent predictor of poor survival and whether it is a better predictor
than other cadherin complex molecules. Any possible clinical use of these
data also awaits further study.
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Methods

Patients and Tumor Specimens
Thymosin [515 Study
Forty-two formalin-fixed, paraffin-embedded tissue blocks were
obtained from patients who underwent breast biopsies or breast resections
between 1989 and 1996 at Yale-New Haven Hospital. Twenty-one blocks of
breast biopsies that yielded a benign primary diagnosis as well an
additional 21 blocks from resections or biopsies that yielded a malignant
diagnosis of either ductal carcinoma in situ (DCIS), infiltrating ductal
carcinoma, or infiltrating lobular carcinoma were selected.

Blocks were

selected by viewing the original pathological slides and obtaining the blocks
from slides that had a large area of tissue representing the primary
diagnosis of each case as well as adjacent areas of normal breast ducts and
lobules to be used as control regions.

P120cas Study
Forty-four tissue blocks were similarly obtained for use in this study
representing patients who underwent curative resections for colorectal
cancer in 1993 and 1994 at Yale-New Haven Hospital. Blocks were selected
for the original slides that showed the junction between the normal colonic
epithelium and the tumor.

Clinical information corresponding to the tissue blocks was obtained
from the Yale-New Haven Hospital pathology database. For the pl20cas
study, records from the Yale-New Haven Hospital Tumor Registry were
also pulled to provide additional clinical information. This work was
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performed under approval of the Yale Human Investigation Committee
(HIC approval #8219)

Antibodies
Thymosin [515 Study
An affinity-purified polyclonal antibody raised against the 11 Cterminal amino acids of thymosin (315 was used. The preparation and
purification of this antibody has previously been described[24].

P120cas Study
The pl20cas-specific monoclonal antibody 12F4 was chosen from a
panel of pl20cas-specific monoclonal antibodies prepared previously[115]
because of its excellent reactivity with formaldehyde-fixed tissue sections.
This antibody binds to an epitope in the carboxy-terminal 121 amino acids of
pl20cas and recognizes all known isoforms of pl20cas that can be
distinguished by immunoprecipitation and western blotting analysis. The
reagent used was affinity purified on protein A sepharose columns.

The preparation of the antibodies was not performed by the principal author
(J.S.G.).

Immunohistochemical Analysis
Standard histological sections were cut from the paraffin blocks,
baked overnight at 60°C, and deparaffinized. Slides were then soaked in
0.75 percent hydrogen peroxide in methanol to quench endogenous
peroxidases. For antigen retrieval, each slide was immersed for five
minutes in 6.5 mM sodium citrate, pH 6.0 in a heated conventional
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pressure cooker[116]. Slides were blocked for one hour in 0.3 percent bovine
serum albumin (BSA) (Sigma Chemical Co., St. Louis, MO) diluted in Tris
buffered saline (TBS), pH 8.0 (immunofluorescence) or normal serum from
the Vectastain ABC kit (Vector Laboratories, Burlingame, CA) diluted in
TBS, pH 8.0 (immunoperoxidase). The slides were incubated for one hour
with the appropriate primary antibody. Polyclonal anti-thymosin (315
antibody was diluted 1:100 in the solution used for blocking, while the
monoclonal antibody against pl20cas (12F4) was diluted 1:500. Slides were
then washed seven times and incubated for one hour with secondary
antibody.

For the immunofluorescent specimens, Cy3-conjugated goat anti¬

rabbit IgG or Cy3-conjugated goat anti-mouse IgG (Jackson
ImmunoResearch Labs, West Grove, PA) diluted 1:500 in TBS, pH 8.0 was
used as the secondary antibody. Biotinylated goat-anti rabbit IgG diluted
1:200 in TBS, pH 8.0 was used for the peroxidase-stained specimens. Slides
were then washed seven times. The peroxidase-stained slides were
incubated 30 minutes in the Vectastain ABC reagent (Vector Laboratories,
Burlingame, CA) — which is composed of avidin and biotinylated
horseradish peroxidase — prepared in TBS, pH 8.0 and then washed for
five minutes in TBS, pH 8.0. All incubations were performed by coating the
tissue with solution and storing the slides in a humidity chamber to prevent
evaporation. The peroxidase-stained slides were further developed using
the Vector DAB kit (Vector Laboratories, Burlingame, CA) — which
employs diaminobenzidine and hydrogen peroxide — for six minutes.
Peroxidase-stained slides were counterstained with hematoxylin. The
immunofluorescent slides were coverslipped with N-propyl galate and
sealed with nail polish, while the peroxidase-stained slides were
coverslipped with Immu-mount (Shandon, Pittsburgh, PA).
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Immunofluorescent slides were stored at -20°C to preserve the signal, while
the peroxidase-stained slides could be stored at room temperature.
Negative controls were prepared by substituting the primary antibody with •
blocking solution in each protocol.

Histological Scoring and Analysis

Thymosin f315 Study
Immunofluorescent slides were examined by two individuals (J.S.G.,
D.L.R.) on an Olympus AX-70 epifluorescence photomicroscope and
representative photographs were obtained. For the peroxidase-stained
specimens, each slide was examined by three observers (J.S.G., R.A.D.G.,
D.L.R.) using standard light microscopy.

For each slide, each observer

assigned up to five scores representative of different pathological elements
contained on that slide. Each slide was scored for the staining of normal
glands, hyperplastic glands, all benign cells, DCIS, and infiltrating cancer.
The scores were based on the average staining of all the cells representing
that diagnosis on the slide. Cells were scored as “0” if the staining was no
greater than background, “1+” if staining was slightly greater than
background, “2+” for an intermediate level of staining, and “3+” for very
intense staining. If the observer deemed there to be insufficient or no tissue
representing a particular diagnosis, a score was not assigned for that slide.
Based on the scores from the three observers, a summary score was
assigned for each element on each slide by totaling the scores if all three
observers assigned scores, or if two observers assigned scores the sum was
multiplied by 3/2 to bring the summary score to the correct scale. A
summary score was not given if one or no observers scored a particular
diagnosis on a slide.
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P120cas Study
All slides were examined by one individual (J.S.G.) on an Olympus
AX-70 epifluorescence photomicroscope.

The internal control regions of

normal colonic epithelium were assessed for strong uniform staining.

The

tumors were compared to the control regions. The loss of pl20cas
expression in the tumors was assessed by the same individual. The slides
were scored as follows.
A score was assigned for the expression of pl20cas both in the entire
tumor seen on each slide and in a 40 X field that was chosen to represent
the tumor area with the least staining on each slide. The latter “worst”
score was used as it was hypothesized that regional loss of pl20cas might
better predict metastasis than the overall level of expression. The percent of
the cell membranes in which there was appreciable p!20cas staining was
used as the basis of the scoring system. A score of “+” was given for greater
than 90 percent staining,

for between 50 and 90 percent, “+/-

between 10 and 50 percent, and

for less than 10 percent.

for

It should be

noted that the percentage of the total cell membranes in which there was
appreciable staining, regardless of intensity, was used for scoring purposes
since the intensity of the signal would be more difficult to quantitate.

Data analysis was accomplished using StatView 4.5 for Macintosh
(Abacus Concepts, Berkeley, CA).
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Variation in the intensity of thymosin (315 expression in breast epithelial cells. Standard
unstained histological sections were stained with an allinity-purilied polyclonal antibody
directed against thymosin (315 and visualized with a peroxidase-based method. Panel A
shows expression of thymosin [315 in benign breast ducts that is just greater than
background. Panel B shows an intermediate expression level as seen in an infiltrating
ductal carcinoma. A very intense staining pattern is seen in a different infiltrating ductal
carcinoma (C). A scoring system was developed for the variation in thymosin [315
expression in breast epithelial cells such that the staining was scored as either
(A).
“2+" (B), or '"3+’' (C).
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Table 1.
cases

Summary of clinical data and thymosin pl5 staining of benign

Primary
Diagnosis
fibroadenoma
fibroadenoma
fibroadenoma
fibroadenoma
fibroadenoma
fibroadenoma
fibroadenoma
fibroadenoma
fibroadenoma
fibrocystic disease
sclerosing adenosis
sclerosing adenosis
sclerosing adenosis
sclerosing adenosis
sclerosing adenosis
atypical hyperplasia
atypical hyperplasia
atypical hyperplasia
atypical hyperplasia
atypical hyperplasia
atypical hyperplasia

Age Score
36
34
24
58
18
25
37
27
60
40
53
56
42
43
60
54
44
29
46
57
63

6.0
4.0
4.0
3.0
7.0
4.0
2.0
8.0
3.0
3.0
3.0
6.0
5.0
3.0
4.0
7.0
5.0
•

3.0
4.0
3.0
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Table 2. Summary of clinical data and thymosin (315 staining of malignant cases
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and not scored while on the other slide the invasive cancer was poorly preserved and not scores
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Table 3. Staining of slides for thymosin (315 grouped by diagnosis
Primary Diagnosis
fibroadenoma
fibrocystic disease
sclerosing adenosis
atypical hyperplasia
all benign
DCIS
infiltrating ductal carcinoma
infiltrating lobular carcinoma
all infiltrating cancer
all malignant
total

Number
of Slides
9
1
5
6
21
6
15
1
16
22
43

Number
Not Scored
0
0
0
1
1
1
2
1
3
4
5

Average
Score
4.6
3.0
4.2
4.4
4.3
6.2
7.1

Percent
Positive
33
0
40
40
35
100
92

•

•

7.1
6.9
5.5

92
94
70

76

Figure 3.
Distribution of cases by score of thymosin (3 15 staining in benign (A) and malignant (B)
breast tissue. Forty-three slides of human breast tissue were stained with an affinitypurified polyclonal antibody to thymosin (315 and conventional peroxidase-based
immunohistochemical methods.

The slides were then scored by three observers for

intensity of staining of the breast epithelium and the combined scores are shown grouped
by benign (20 cases scored) or malignant (18 cases scored) primary diagnoses. Each bar
on the histograms represents the number of cases with a score in a range including the
number on the axis at its left margin and up to the number on the axis at its right margin.
Each curve represents a normal distribution with the same mean and standard deviation as
the scores on that histogram.

The histograms show that the score of five seems to

separate the benign from the malignant cases with the majority of benign cases scoring
less than five, and all but one of the malignant cases scoring five or greater.
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Table 4. Contingency table of benign or malignant slides versus “positive” or
“negative” staining for thymosin (315
Negative Positive Totals
Benign
Malignant
Totals

13
1
14

7
17
24

38

y~ = 14.387, Fischer’s exact p-value = 0.0002
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The tumors express pl2()cas in varying intensities and in different percentages of their membranes. As a general rule, the intensity
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Table 5. Summary of histopathologic data and p!20cas staining of cases analyzed
Number

Tumor
Location

Tumor
Size
(in cm)

Grade

Stage

Node
Status

Presence
Presence of
Overall
of Lympho- Mucinous or Score
vascular
Signet Ring
Invasion
Features
1
right colon 5.0
2
I
negative no
no
+ /2
right colon 2.2
2
II
negative no
no
+ /3
right colon 4.5
_
3
III
positive yes
yes
4
right colon 4.5
2
I
negative no
no
+ /5
right colon 4.0
2
II
negative no
no
+
6
right colon 4.0
2
IV
positive no
no
+ /2
7
right colon 4.5
II
negative no
no
+ /8
right colon 5.0
2
II
negative no
no
+
2
9
right colon 6.0
III
positive no
no
+ /- 10
right colon 2.5
2
III
positive no
no
+
11
right colon 10.0
3
II
negative no
yes
+ /-2
12
right colon 9.0
IV
positive yes
no
+ /-13
right colon 5.0
3
IV
positive yes
no
+ /- 14
right colon 3.5
2
II
negative no
no
+
2
15
right colon 3.2
I
negative no
no
+ /2
16
rectum
4.0
rv
positive yes
no
+ /17
sigmoid
6.0
3
IV
positive yes
no
+ /2
18
right colon 3.8
hi
positive yes
no
+ /2
19
right colon 3.0
ii
negative no
no
+ /2
20
left colon
7.5
ii
negative yes
no
+ /-21
right colon 2.0
3
IV
positive yes
no
+ /22
rectum
3.5
2
III
positive yes
no
+ /2
23
unknown
3.5
II
negative no
no
+ /2
24
left colon
5.0
III
positive yes
no
+ /25
rectum
2.0
2
I
negative no
no
+ /2
26
right colon 4.0
III
positive no
no
+ /-27
right colon 2.5
IV
2
positive no
no
+
28
unknown
13.0
IV
3
positive yes
yes
+
2
29
right colon 3.5
II
negative yes
no
+ /2
30
IV
sigmoid
5.0
negative yes
no
+ /31
right colon 7.0
III
3
positive yes
yes
+ /32
4.0
rectum
II
2
negative no
no
+ /33
unknown
III
unknown 3
positive no
no
+
2
34
right colon 2.0
I
negative no
no
+ /2
35
3.0
II
sigmoid
negative yes
no
+
2
36
right colon 4.5
II
negative no
no
+
2
37
unknown
2.0
III
positive no
no
+
2
38
sigmoid
4.0
III
positive yes
no
+
39
right colon 8.0
II
negative no
3
no
+ /2
40
II
negative no
left colon
5.0
no
+ /2
41
II
negative yes
right colon 6.0
no
+ /2
42§
III
positive no
left colon
4.0
no
+ /43t
2
II
negative no
left colon
3.0
no
+
44*
III
positive yes
left colon
5.0
3
yes
45*
5.0
3
III
positive yes
yes
left colon
+ /§ this patient had a bowel resection for colorectal cancer about 20 years before this tumor was diagnosed
t this tumor is a recurrence of a colorectal cancer that was resected 439 days before this tumor was resected
* these two slides are from the same tumor but were inadvertently both stained and scored separately

Worst
Score
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+ /-

+ /-

Table 6. Summary of clinical data and p!20cas staining of cases analyzed
Number

Age

Gender Alive Survival Presence of
Recurrence- Overall Worst
or
Days
Subsequent
Free Days
Score
Score
Dead
Metastasis
1
87
female
alive
941
no
941
+ /+ /- 2
73
female
alive
742
no
742
+ /+ /3
67
male
alive
762
no
762
4
89
female
alive
652
no
652
+ /+ /5
65
male
alive
742
no
742
+
+ /6
58
male
alive
587
no
587
+ /+ /7
76
male
alive
714
no
714
+ /+ /-8
85
female
alive
611
no
611
+
+ /9
87
male
alive
755
no
755
+ /- 10
64
female
alive
737
no
737
+
+ /11
83
female
dead
487
no
487
+ /- + /- 12
88
male
dead
574
no
574
+ /- 13
61
female
dead
200
no
200
+ /- 14
87
female
dead
582
no
582
+
+ /15
62
female
alive
28
no
28
+ /.
16
54
female
alive
45
no
45
+ /17
42
male
dead
176
no
176
+ /+ /18
51
female
alive
997
yes
997
+ /+ /19
70
female
alive
699
no
699
+ /+ /20
74
female
alive
881
no
881
+ /- + /- 21
55
female
alive
904
no
904
+ /+ /- 22
40
male
alive
856
no
856
+ /+ /- 23
55
male
alive
321
no
321
+ /+ /24
71
male
alive
797
no
797
+ /+ /-25
62
male
alive
779
no
779
+ /+ /- _
26
84
female
dead
566
no
566
+ /-27
63
female
dead
449
no
449
+
+ /28
88
74
female
dead
no
74
+
+ /- 29
47
male
alive
841
yes
519
+ /+ /-30
62
female
alive
343
no
343
+ /+ /-31
alive
70
male
1035
no
1035
+ /+ /32
66
alive
male
1206
no
1206
+ /+ /33
62
female
dead
539
no
539
+
+ /34
67
male
dead
583
yes
154
+ /+ /35
77
male
alive
1231
no
1231
+
+ /36
79
male
alive
1003
no
1003
+
+ /37
88
male
alive
1325
no
1325
+
+ /38
68
male
alive
1213
no
1213
+
+ /- 39
1050
81
female
alive
no
1050
+ /+ /40
62
dead
1111
male
no
1111
+ /+ /- 41
alive
1150
70
male
no
1150
+ /+ /- 42§
alive
845
81
female
no
845
+ /+ /- female
alive
1088
no
1088
+
61
+ /43t
44*
164
67
male
dead
yes
58
164
45*
67
male
dead
yes
58
+ /+ /§ this patient had a bowel resection for colorectal cancer about 20 years before this tumor was diagnosed
t this tumor is a recurrence of a colorectal cancer that was resected 439 days before this tumor was resected
* these two slides are from the same tumor but were inadvertently both stained and scored separately
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> 50 percent

< 50 percent

Overall pl20cas Expression

Figure 6.
Tumor size for colorectal cancers with overall membrane expression of pl20cas greater
than 50 percent versus those with expression less than 50 percent. Standard pathological
sections from curative resections for colorectal cancer were stained with a monoclonal
antibody directed at pl20cas and detected with an immunofluorescent secondary
antibody. Slides were then assessed for pl20cas expression. Thirty-seven slides were
scored as having greater than 50 percent of pl20cas expression overall and eight slides
were scored for less than 50 percent expression. The tumor size was unknown for one
case with greater than 50 percent staining. The histogram shows mean tumor size (+
standard error) for each group (unpaired t-test p-value = 0.0120).
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Stage

Stage

Figure 7.
Distribution of cases by stage for tumors with a least staining area showing retained
pl20cas expression (A) or complete loss of pl20cas (B). Standard pathological sections
from curative resections of colorectal tumors were stained with a monoclonal antibody
directed at pl20cas and detected with an immunofluorescent secondary antibody. Slides
were scored for percent of pl20cas expression overall and in a high power field that
stained the least. The pathological stage at the time of the operation was determined from
pathology records. Thirty-seven slides had a high power field with complete loss (less
than 10 percent) pl20cas staining, and eight slides had some retained expression of
pl20cas in the least staining areas. The distribution of stages for each group of cases is
shown in the histograms above. It can be seen that most of the cases with greater than 50
percent pl20cas expression are AJCC Stage I and II, whereas most of the cases with
complete loss of staining are Stage III and IV.
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Table 7. Contingency table of stage versus complete loss or expression of pl20cas
the tumor area with the least staining

Low
High
Totals

Expression
21
16
37

Complete Loss
1
7
8

= 5.156, Fischer’s exact p-value = 0.0470

Totals
22
23
45

85

Worst Score

+ /-

+ /-Worst Score

Figure 8.
Distribution of “worst” scores of pl20cas expression by nodal status. Forty-five standard
surgical pathological sections of colorectal cancers were stained with a monoclonal
antibody directed at pl20cas and detected with an immunofluorescent secondary
antibody. Slides were scored for percent of pl20cas expression overall and in a high
power field selected for having the least staining. The presence or absence of metastasis
to lymph nodes for each case was determined from pathology records. Twenty-three
cases were node negative and 22 were node positive. The distribution of the assigned
scores for pl20cas expression in the least staining areas is shown for node negative (A)
and node positive (B) cases. The scores shown are “+/-” for between 50 and 90 percent
membrane staining of pl20cas, “+/-

for between 10 and 50 percent staining, and

for

less than 10 percent staining. It can be seen that most of the node negative cases have
greater than 10 percent staining of pl20cas in the least staining area, whereas the node
positive cases have a much more even distribution for amount of pl20cas expression.
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Table 8. Contingency table of nodal status versus complete loss or expression of
p!20cas in the tumor area with the least staining

Negative
Positive
Totals

Expression
22
15
37

Complete Loss
1
7
8

X~ = 5.805, Fischer’s exact p-value = 0.0426

Totals
23
22
45
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Figure 9.
Distribution of “worst” scores of pl20cas expression by absence (A) or presence (B) of
lymphovascular invasion. Forty-five standard surgical pathological sections of colorectal
cancers were stained with a monoclonal antibody directed at pl20cas and detected with
an immunofluorescent secondary antibody. Slides were scored for percent of pl20cas
expression overall and in a high power field selected for having the least staining. The
presence or absence of histologically observed lymphovascular invasion was determined
from the pathology reports. Twenty-six cases did not have lymphovascular invasion,
while 19 did. The scores shown are “+/-” for between 50 and 90 percent membrane
staining of pl20cas, “+/- -” for between 10 and 50 percent staining, and

for less than

10 percent staining. Most of the cases without lymphovascular invasion have greater
than 10 percent staining of pl20cas in a least staining area, whereas the staining patterns
of the cases with lymphovascular invasion are more evenly distributed.
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Table 9. Contingency table of the presence or absence of lymphovascular invasion
versus greater than or less than 50 percent pl20cas expression in the tumor area
that stained the least

Absent
Present
Totals

> 50 percent
17
5
22

< 50 percent
9
14
23

yp- = 6.706, Fischer’s exact p-value = 0.0156

Totals
26
19
45
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Days after Operation

Days after Operation

Figure 10.
Kaplan-Meier Life Table Analysis of survival for patients with colorectal tumors having
greater than or less than 50 percent pl20cas expression “overall” (A) and for patients
having colorectal tumors with greater than or less than 10 percent pl20cas expression in
the least staining area (B). Forty-five standard surgical pathology slides from patients
having a resection of a colorectal cancer were stained with a monoclonal antibody
specific for pl20cas and a Cy3-conjugated secondary antibody. The slides were scored
for pl20cas expression overall and in a high power field selected for having the least
staining. Follow-up data was collected from the Yale-New Haven Tumor Registry for
each patient. Survival is significantly worse for the patients with less than 50 percent
pl20cas expression overall than for those with greater than 50 percent pl20cas
expression (p = 0.0126). Survival is also worse for the patients whose tumors had less
than 10 percent expression of pl20cas in the least staining area compared to those with
greater than 10 percent expression (p - 0.0162).
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Figure 11.
Kaplan-Meier Life Table Analysis of recurrence-free survival for patients with colorectal
tumors having greater than or less than 50 percent pl20cas expression “overall” (A) and
for tumors with greater than or less than 10 percent pl20cas expression in the least
staining area (B). Forty-five standard surgical pathology slides from colorectal cancer
resections were stained with a monoclonal antibody specific for pl20cas and detected
with an immunofluorescent secondary antibody. The slides were scored for pl20cas
expression overall and in a high power field selected for having the least staining.
Follow-up data was collected from the Yale-New Haven Tumor Registry and the hospital
pathology database.

Disease-free survival is significantly worse for the patients with less

than 50 percent pl20cas expression overall than for those with greater than 50 percent
expression (p = 0.0313).

Disease-free survival is also worse for the patients whose

tumors have less than 10 percent expression of pl20cas in the least staining area
compared to those with greater than 10 percent expression (p = 0.0369).
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